# Oralee J. Varnado

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/oralee-j-varnado/

## Facts

| Field | Value |
| --- | --- |
| Citations | 365 |
| Field | Migraine and Headache Studies |
| h-index | 11 |
| i10-index | 12 |
| Last Known Institution | Eli Lilly (United States) |
| OpenAlex ID | https://openalex.org/A5065548484 |
| ORCID iD | 0000-0001-8054-2544 |
| Works | 32 |

## Researcher papers

- [Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years](https://scholariq.org/papers/similar-efficacy-and-safety-of-once-weekly-dulaglutide-in-patients-with-type-2/)
- [Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon](https://scholariq.org/papers/treatment-and-prevention-of-severe-hypoglycaemia-in-people-with-diabetes-current/)
- [Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial](https://scholariq.org/papers/comparing-the-efficacy-and-safety-of-galcanezumab-versus-rimegepant-for/)
- [Factors associated with fear of hypoglycaemia among the T1D Exchange Glu population in a cross-sectional online survey](https://scholariq.org/papers/factors-associated-with-fear-of-hypoglycaemia-among-the-t1d-exchange-glu/)
- [Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial](https://scholariq.org/papers/efficacy-and-safety-of-dulaglutide-in-older-patients-a-post-hoc-analysis-of-the/)
- [Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study](https://scholariq.org/papers/treatment-patterns-for-calcitonin-gene-related-peptide-monoclonal-antibodies/)
- [Patient‐reported outcome results in patients with type 2 diabetes treated with once‐weekly dulaglutide: data from the <scp>AWARD</scp> phase <scp>III</scp> clinical trial programme](https://scholariq.org/papers/patient-reported-outcome-results-in-patients-with-type-2-diabetes-treated-with/)
- [Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9)](https://scholariq.org/papers/patient-reported-outcomes-in-patients-with-type-2-diabetes-treated-with/)
- [Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene–related peptide inhibitors vs other preventive migraine treatments in the United States](https://scholariq.org/papers/health-care-resource-utilization-and-costs-associated-with-treatment-among/)
- [Examining the evidence for weight management in individuals with type 2 diabetes](https://scholariq.org/papers/examining-the-evidence-for-weight-management-in-individuals-with-type-2-diabetes/)
- [Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States](https://scholariq.org/papers/treatment-patterns-healthcare-resource-utilization-and-direct-costs-among/)

## Researcher topics

- [Migraine and Headache Studies](https://scholariq.org/topics/migraine-and-headache-studies/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Nicotinic Acetylcholine Receptors Study](https://scholariq.org/topics/nicotinic-acetylcholine-receptors-study/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)

## Researcher university

- [Eli Lilly (United States)](https://scholariq.org/institutions/eli-lilly-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.